Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_assertion type Assertion NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_head.
- NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_assertion description "[Currently, a humanized anti-4-1BB is in clinical trials in patients with solid tumors, including melanoma, renal carcinoma, and ovarian cancer, and so far seems to have a favorable toxicity profile.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_provenance.
- NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_assertion evidence source_evidence_literature NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_provenance.
- NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_assertion SIO_000772 22532596 NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_provenance.
- NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_assertion wasDerivedFrom befree-20140225 NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_provenance.
- NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_assertion wasGeneratedBy ECO_0000203 NP439049.RAwbWcy7RFw4hWq1_CQZGW9tV9gvjcv5TS0mswqOiXJiI130_provenance.